Legend Biotech’s Q2 2025: Strong CARVYKTI Sales and Strategic Growth

Legend Biotech Corporation ( (LEGN) ) has released its Q2 earnings. Here is a breakdown of the information Legend Biotech Corporation presented to its investors.

Legend Biotech Corporation, a leader in the cell therapy sector, is renowned for its innovative treatments in cancer care, particularly its CAR-T cell therapy, CARVYKTI, used for treating relapsed or refractory multiple myeloma. In its second quarter of 2025, Legend Biotech reported significant achievements, including net trade sales of approximately $439 million for CARVYKTI and positive long-term outcomes from its CARTITUDE-1 study, with one-third of patients remaining progression-free for five years. The company also highlighted its expansion into new markets and regulatory updates, such as the FDA’s removal of certain monitoring requirements for CARVYKTI.

Financially, Legend Biotech reported a total revenue of $255.1 million for the quarter, with collaboration revenue seeing a substantial increase due to CARVYKTI sales. Despite a net loss of $125.4 million, the company achieved an adjusted net income of $10.1 million, marking a positive shift from the previous year’s adjusted net loss. Research and development expenses decreased, reflecting scaled-back clinical production, while selling and distribution expenses rose due to expanded commercial activities.

Legend Biotech’s strategic focus remains on advancing its pipeline of CAR-T programs and achieving profitability by 2026. The company’s cash position, with cash and equivalents totaling $1.0 billion, provides a financial runway into 2026, supporting its growth and innovation objectives. As Legend Biotech continues to enhance its market presence and therapeutic offerings, it remains committed to delivering groundbreaking cell therapy solutions to patients worldwide.